Top

Published in:

01-06-2009 | Review

Hepatitis C Virus and Inflammatory Bowel Disease

Authors: Todd L. Horn, Joel Reynolds, Willem de Villiers, Luis R. Peña

Published in: Digestive Diseases and Sciences | Issue 6/2009

Abstract

Gastroenterologists frequently treat patients with complex illnesses such as chronic hepatitis C infections and inflammatory bowel disease (IBD). Occasionally, a patient will present with these two diseases which behave very differently and the treatment for one may potentially exacerbate the other. The purpose of this article is to review the current literature regarding hepatitis C virus therapy in the setting of IBD as well as the effects of common IBD therapies on the hepatitis C virus. Based on limited data, anti-viral therapy is probably safe in patients with well-controlled IBD, but there might be a risk of causing new onset of IBD. Also, it does not appear that the commonly used medications for IBD have much of an effect on the hepatitis C virus (HCV) or its course.

Longo F, Hebuterne X, Tran A, et al. Prevalence of hepatitis C in patients with chronic inflammatory bowel disease in the region of Nice and evaluation of risk factors. Gastroenterol Clin Biol. 2000;24(1):77–81.PubMed

Bronowicki JP, Barraud H, Peyrin-Biroulet L. Epidemiology and natural history of hepatitis C. Rev Prat. 2005;55(6):607–614.PubMed

Biancone L, Pavia M, Del Vecchio Blanco G, et al. Hepatitis B and C virus infection in Crohn’s disease. Inflamm Bowel Dis. 2001;7(4):287–294. doi:10.1097/00054725-200111000-00002.PubMedCrossRef

Khalil A, Lucidarme D, Desurmont P, et al. Crohn’s disease associated with interferon and ribavirin treatment for chronic hepatitis C. Gastroenterol Clin Biol. 2005;29(2):193–196. doi:10.1016/S0399-8320(05)80736-5.PubMedCrossRef

Villa F, Rumi MG, Signorelli C, et al. Onset of inflammatory bowel diseases during combined alpha-interferon and ribavirin therapy for chronic hepatitis C: report of two cases. Eur J Gastroenterol Hepatol. 2005;17(11):1243–1245. doi:10.1097/00042737-200511000-00015.PubMedCrossRef

Mavrogiannis C, Papanikolaou IS, Elefsiniotis IS, et al. Ulcerative colitis associated with interferon treatment for chronic hepatitis C. J Hepatol. 2001;34(6):964–965. doi:10.1016/S0168-8278(01)00022-8.PubMedCrossRef

Sprenger R, Sagmeister M, Offner F. Acute ulcerative colitis during successful interferon/ribavirin treatment for chronic hepatitis. Gut. 2003;52(12):1728–1733. doi:10.1136/gut.52.12.1728.CrossRef

Niki T, Nishida K, Honsako Y, et al. A case of ulcerative colitis along with characteristic features on computed tomography (CT), developed by the treatment with interferon for chronic hepatitis C. Nippon Shokakibyo Gakkai Zasshi. 2001;98(4):399–404.PubMed

Watanabe T, Inoue M, Harada K, et al. A case of exacerbation of ulcerative colitis induced by combination therapy with PEG-interferon alpha-2b and ribavirin. Gut. 2006;55(11):1682–1683. doi:10.1136/gut.2006.105197.PubMedCrossRef

10.

Mitoro A, Yoshikawa M, Yamamoto K, et al. Exacerbation of ulcerative colitis during alpha-interferon therapy for chronic hepatitis C. Intern Med. 1993;32(4):327–331. doi:10.2169/internalmedicine.32.327.PubMedCrossRef

11.

Yamamoto Y, Sakatani N, Yano S, et al. Interferon-induced IBD-like acute colitis–two cases of patients with chronic active hepatitis. Nippon Shokakibyo Gakkai Zasshi. 1995;92(9):1293–1296.PubMed

12.

Cottone M, Magliocco A, Trallori G, et al. Clinical course of inflammatory bowel disease during treatment with interferon for associated chronic active hepatitis. Ital J Gastroenterol. 1995;27(1):3–4.PubMed

13.

Bargiggia S, Thorburn D, Anderloni A, et al. Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study. Aliment Pharmacol Ther. 2005;22(3):209–215.PubMedCrossRef

14.

Tilg H, Vogelsang H, Ludwiczek O, et al. A randomized placebo-controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut. 2003;52(12):1728–1733. doi:10.1136/gut.52.12.1728.PubMedCrossRef

15.

Esteve M, Saro C, Gonzalex-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut. 2004;53:1363–1365. doi:10.1136/gut.2004.040675.PubMedCrossRef

16.

Ueno Y, Tanaka S, Shimamoto M, et al. Infliximab therapy for Crohn’s disease in a patient with chronic hepatitis B. Dig Dis Sci. 2005;50:163–166. doi:10.1007/s10620-005-1295-8.PubMedCrossRef

17.

Garcia-Sanchez M, Gomez-Camacho F, Poyato-Gonzalez A, et al. Infliximab therapy in a patient with Crohn’s disease and chronic hepatitis B virus infection. Inflamm Bowel Dis. 2004;10:701–702. doi:10.1097/00054725-200409000-00035.CrossRef

18.

Wendling D, Auge B, Bettinger D, et al. Reactivation of a latent precore mutant hepatitis B virus-related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis. 2005;64:788–789. doi:10.1136/ard.2004.031187.PubMedCrossRef

19.

Ostuni P, Botsios C, Punzi L, et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low-dose methotrexate. Ann Rheum Dis. 2003;62:686–687. doi:10.1136/ard.62.7.686.PubMedCrossRef

20.

Michel M, Duvoux C, Hezode C, et al. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult-onset Still’s disease. J Rheum. 2003;30:1624–1625.PubMed

21.

Peterson JR, Hsu FC, Simkin PA, et al. Effect of tumor necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis. 2003;62:1078–1082. doi:10.1136/ard.62.11.1078.PubMedCrossRef

22.

Oniankitan O, Duvoux C, Challine D, et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheum. 2004;31:107–109.PubMed

23.

Parke FA, Reveille JD. Anti-tumor necrosis factor agents for RA in the setting of chronic hepatitis C infection. Arthritis Rheum. 2004;51:800–804. doi:10.1002/art.20702.PubMedCrossRef

24.

Roux CH, Brocq O, Breuil V, et al. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology. 2006;45(10):1294–1297. doi:10.1093/rheumatology/kel123.PubMedCrossRef

25.

Aslanidis S, Vassiliadis T, Pyrpasopoulou A, et al. Inhibition of TNF-alpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases. Clin Rheumatol. 2007;26(2):261–264. doi:10.1007/s10067-006-0394-z.PubMedCrossRef

26.

Pitarch G, Sanchez-Carazo JL, Mahiques L, et al. Treatment of psoriasis with adalimumab. Clin Exp Dermatol. 2007;32(1):18–22.PubMed

27.

Campbell S, Ghosh S. Infliximab therapy for Crohn’s disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol. 2001;13:191–192. doi:10.1097/00042737-200102000-00016.PubMedCrossRef

28.

Holtmann MH, Galle PR, Neurath MF. Treatment of patients with Crohn’s disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF. Am J Gastroenterol. 2003;98:504–505. doi:10.1111/j.1572-0241.2003.07245.x.PubMedCrossRef

29.

Zein NN, Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naïve patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol. 2005;42(3):315–322. doi:10.1016/j.jhep.2004.11.025.PubMedCrossRef

30.

Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol. 2006;21(9):1366–1371.PubMedCrossRef

31.

Stangl JR, Carroll KL, Illichmann M, et al. Effect of antimetabolite immunosuppressants on Flaviviridae, including hepatitis C virus. Transplantation. 2004;77(4):562–567. doi:10.1097/01.TP.0000114610.40412.C6.PubMedCrossRef

32.

Samonakis DN, Triantos CK, et al. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl. 2005;11(4):384–385. doi:10.1002/lt.20344.CrossRef

33.

Zekry A, Gleeson M, Guney S, et al. A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection. Liver Transpl. 2004;10(1):52–57. doi:10.1002/lt.20000.PubMedCrossRef

34.

Walter T, Dumortier J, Guillaud O, et al. Factors influencing the progression of fibrosis in patients with recurrent hepatitis C after liver transplantation under antiviral therapy: a retrospective analysis of 939 liver biopsiesin a single center. Liver Transpl. 2007;13(2):294–301. doi:10.1002/lt.21000.PubMedCrossRef

35.

Contreras AM, Monteon FJ, Flores MR, et al. Drug-related hepatotoxicity in a renal transplant recipient with long-term survival and hepatitis C. Ann Hepatol. 2007;6(1):70–73.PubMed

36.

Mok MY, Ng WL, Yuen MF, et al. Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin Exp Rheumatol. 2000;18(3):363–368.PubMed

37.

Kujawska A, Clements M, Wise CM, et al. Hepatitis C and methotrexate. Arthritis Rheum. 2003;49(6):843–845.PubMedCrossRef

38.

Firpi RJ, Zhu H, Morelli G, et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl. 2006;12(1):51–57. doi:10.1002/lt.20532.PubMedCrossRef

39.

Schiavon LL, Carvalho-Filho RJ, Narciso-Schiavon JL, et al. Impact of cyclosporine-based immunosuppressive therapy on liver histology of hepatitis C virus-infected renal transplant patients. Hepatology. 2008;48(1):348–349. doi:10.1002/hep.22331.PubMedCrossRef

40.

Wiesner RH, Shorr JS, Steffen BJ, et al. Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl. 2005;11(7):750–759. doi:10.1002/lt.20453.PubMedCrossRef

41.

Sánchez-Bueno F, Ortiz ML, Bermejo J, et al. Prognostic factors for hepatitis C recurrence in patients undergoing orthotopic liver transplantation. Transpl Immunol. 2006;17(1):47–50. doi:10.1016/j.trim.2006.09.029.PubMedCrossRef

42.

Kato T, Gaynor JJ, Yoshida H, et al. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at 1 year. Transplantation. 2007;84(7):829–835.PubMedCrossRef

Title: Hepatitis C Virus and Inflammatory Bowel Disease
Authors: Todd L. Horn
Joel Reynolds
Willem de Villiers
Luis R. Peña
Publication date: 01-06-2009
Publisher: Springer US
Published in: Digestive Diseases and Sciences / Issue 6/2009
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-008-0489-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Hepatitis C Virus and Inflammatory Bowel Disease

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2009

For Patients with Colorectal Cancer, the Long-Term Use of Statins Is Associated with Better Clinical Outcomes

Sensitivity of Ultrasonography for Gastric Cancer Diagnosis in Symptomatic Patients

The Effect of Hypericum perforatum (St. John’s Wort) on Experimental Colitis in Rat

Endothelial Markers in Schistosomiasis Patients With or Without Portal Hypertension

Access to Treatment of Hepatitis C in Prison Inmates

A Blinded Pilot Comparison of Capsule Endoscopy and Small Bowel Histology in Unresponsive Celiac Disease

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page